TME Pharma Employee Directory
Pharmaceutical ManufacturingBerlin, Germany11-50 Employees
TME Pharma is a clinical-stage pharmaceutical company focused on developing therapies for aggressive cancers by targeting the tumor microenvironment. The company is based in Berlin, Germany, and employs 11-50 people. Its lead candidate NOX-A12 is described as acting through two mechanisms of action and is being developed for glioblastoma, with topline clinical results reported. NOX-A12 is characterized as a CXCL12 inhibitor within its mechanism. Regulatory updates in 2025 included the FDA Fast Track designation for NOX-A12 in combination with radiotherapy and bevacizumab for glioblastoma and the approval by the FDA and German BfArM of the design of a randomized Phase 2 trial in glioblastoma.